[The Business Times] Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

After investing six years in R&D, NYB is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client.

‍

Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.

‍

Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.

‍

‍Read the full article on The Business Times

‍

‍

‍